INTRODUCTIONIn order to study the therapeutic mechanisms ofemodin,an extract of Rhubarb （Rhizoma et RadixRhei,a traditional Chinese herbal medicine）,andsandostatin in the treatment of acute necrotizingpancreatitis ...INTRODUCTIONIn order to study the therapeutic mechanisms ofemodin,an extract of Rhubarb （Rhizoma et RadixRhei,a traditional Chinese herbal medicine）,andsandostatin in the treatment of acute necrotizingpancreatitis （ANP）,we used the two drugs in ratmodels of the disease and observed the changes ofplasma thromboxane-2（TXB<sub>2</sub>）,6-keto-prostaglandin F<sub>1α</sub>(6-keto-PGF<sub>1α</sub>)and prostaglandinE<sub>2</sub>（PEG<sub>2</sub>）.展开更多
Objective: Octreotide three times daily is re-ported to reduce daily insulin by 50% in patients with Type 1 DM. Therefore, we assessed the impact of long acting Octreotide (Sandostatin LAR) monthly Intramuscular admin...Objective: Octreotide three times daily is re-ported to reduce daily insulin by 50% in patients with Type 1 DM. Therefore, we assessed the impact of long acting Octreotide (Sandostatin LAR) monthly Intramuscular administration in a subject with Type 1 DM. Methods: A 32-year-old man with Type 1 DM of 16 years participated after obtaining informed consent. He had no microvascular or macrovascular complications. He continued the present insulin regimen for four weeks. IM Sandostatin LAR 20 mg was initiated and increased at four weeks to 30 mg. He was followed every four weeks for six months. Insulin regimen was adjusted every two weeks based on blood glucose before meals, bedtime and on onset of hypoglycemic symptoms. He continued other medications, previous diet and activity Assessment of HbA1c, serum electrolytes, urea nitrogen, creatinine, TSH, free T4, liver enzymes, complete blood cell counts, vitamin B12, lipids and insulin regimen were performed at the initiation and end of the study. Results: HbA1c declined from 9 to 8% with reduction in daily insulin dose from 55 to 43 units, with a major reduction in insulin Glargine, 50 to 40 units. Body weight remained unaltered. Other laboratory tests including gallbladder examina-tion remained unchanged Conclusion: Monthly Sandostatin LAR administration may improve glycemic control with less insulin in Type 1 DM.展开更多
Objective: To investigate pancreatic ischemia and abnormal metabolism of eicosanoids in acute haemorrhagic necrotizing pancreatitis (AHNP) and the effects of emodin or sandostatin on them. Methods: In rats with AHNP t...Objective: To investigate pancreatic ischemia and abnormal metabolism of eicosanoids in acute haemorrhagic necrotizing pancreatitis (AHNP) and the effects of emodin or sandostatin on them. Methods: In rats with AHNP triggered with sodium taurocholate, the pancreatic blood flow (PBF) was detected with computerized tissue blood flowmeter, and plasma thromboxane B2(TXB2), 6-keto-prostaglandin Fla(6-keto-PGF1a) and prostaglandin E2(PGE2) were determined with radioimmunoassay. Results: There was a significant decrease of PBF in the early stage of AHNP. Compared with that in the non-treated group, significant improvement of PBF was demonstrated in emodin as well as in sandostatin group which showed reduced PBF following infusion of sandostatin before AHNP was triggered. In the non-treated group, plasma TXB2 was significantly higher, with an increase of 4.5 times, than that in sham-operated group, while 6-keto-PGF1a and PGE2 tended to decrease. The above mentioned abnormal metabolism of eicosanoids was blocked either in emodin or in sandostatin group in which lessened damage of acinar cells was shown by pathologic scoring or transmission electron microscope. Both groups shared significantly lower mortalities than the non-treated group. Conclusions: Either emodion or sandostatin could partly reverse the decrease of PBF in the early stage of AHNP, which may be ascribed at least in part to inhibition of abnormal metabolism of eicosanoids and improvement of pancreatic cytoprotection, and combined application of the two drugs is likely to have synergetic action.展开更多
基金National Natural Science Foundation of China,No.35970891
文摘INTRODUCTIONIn order to study the therapeutic mechanisms ofemodin,an extract of Rhubarb （Rhizoma et RadixRhei,a traditional Chinese herbal medicine）,andsandostatin in the treatment of acute necrotizingpancreatitis （ANP）,we used the two drugs in ratmodels of the disease and observed the changes ofplasma thromboxane-2（TXB<sub>2</sub>）,6-keto-prostaglandin F<sub>1α</sub>(6-keto-PGF<sub>1α</sub>)and prostaglandinE<sub>2</sub>（PEG<sub>2</sub>）.
文摘Objective: Octreotide three times daily is re-ported to reduce daily insulin by 50% in patients with Type 1 DM. Therefore, we assessed the impact of long acting Octreotide (Sandostatin LAR) monthly Intramuscular administration in a subject with Type 1 DM. Methods: A 32-year-old man with Type 1 DM of 16 years participated after obtaining informed consent. He had no microvascular or macrovascular complications. He continued the present insulin regimen for four weeks. IM Sandostatin LAR 20 mg was initiated and increased at four weeks to 30 mg. He was followed every four weeks for six months. Insulin regimen was adjusted every two weeks based on blood glucose before meals, bedtime and on onset of hypoglycemic symptoms. He continued other medications, previous diet and activity Assessment of HbA1c, serum electrolytes, urea nitrogen, creatinine, TSH, free T4, liver enzymes, complete blood cell counts, vitamin B12, lipids and insulin regimen were performed at the initiation and end of the study. Results: HbA1c declined from 9 to 8% with reduction in daily insulin dose from 55 to 43 units, with a major reduction in insulin Glargine, 50 to 40 units. Body weight remained unaltered. Other laboratory tests including gallbladder examina-tion remained unchanged Conclusion: Monthly Sandostatin LAR administration may improve glycemic control with less insulin in Type 1 DM.
文摘Objective: To investigate pancreatic ischemia and abnormal metabolism of eicosanoids in acute haemorrhagic necrotizing pancreatitis (AHNP) and the effects of emodin or sandostatin on them. Methods: In rats with AHNP triggered with sodium taurocholate, the pancreatic blood flow (PBF) was detected with computerized tissue blood flowmeter, and plasma thromboxane B2(TXB2), 6-keto-prostaglandin Fla(6-keto-PGF1a) and prostaglandin E2(PGE2) were determined with radioimmunoassay. Results: There was a significant decrease of PBF in the early stage of AHNP. Compared with that in the non-treated group, significant improvement of PBF was demonstrated in emodin as well as in sandostatin group which showed reduced PBF following infusion of sandostatin before AHNP was triggered. In the non-treated group, plasma TXB2 was significantly higher, with an increase of 4.5 times, than that in sham-operated group, while 6-keto-PGF1a and PGE2 tended to decrease. The above mentioned abnormal metabolism of eicosanoids was blocked either in emodin or in sandostatin group in which lessened damage of acinar cells was shown by pathologic scoring or transmission electron microscope. Both groups shared significantly lower mortalities than the non-treated group. Conclusions: Either emodion or sandostatin could partly reverse the decrease of PBF in the early stage of AHNP, which may be ascribed at least in part to inhibition of abnormal metabolism of eicosanoids and improvement of pancreatic cytoprotection, and combined application of the two drugs is likely to have synergetic action.
